Ir para o conteúdo principal

Tempest Therapeutics (NASDAQ: TPST) — Perfil da empresa, notícias e dados financeiros

Logo de Tempest Therapeutics
TPST Tempest Therapeutics
Tempest Therapeutics primary media
Perfil da empresa

Tempest Therapeutics

Tempest Therapeutics (NASDAQ:TPST) is focused on discovering and developing a diverse portfolio of small molecule therapeutics. Their work is dedicated to addressing a wide range of diseases with significant unmet medical needs. Central to their operations are innovative projects aimed at targeting key pathways in cancer biology, immune-oncology, and inflammation. By leveraging cutting-edge science, Tempest aims to advance these therapeutics from conception through clinical development, with the objective of bringing transformative treatments to patients worldwide. Their commitment to research and development underscores a broader mission to improve healthcare outcomes and enhance the quality of life for patients grappling with serious diseases.

Resumo

Public USParticipação acionária
2011Ano de fundação
17Funcionários
California, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Tempest Therapeutics

  • TPST-1120, a selective PPARa antagonist aimed at treating various cancers by targeting tumor and immune cells.
  • TPST-1495, a dual EP2/EP4 antagonist for solid tumors, enhancing antitumor immunity.
  • Preclinical programs focusing on novel targets in immuno-oncology to stimulate the immune system against cancer.
  • Collaboration projects for the development and commercialization of proprietary oncology therapies.
  • Research initiatives to identify and validate next-generation targets in cancer therapy.

equipe executiva do Tempest Therapeutics

  • Matthew AngelPresident, CEO & Director
  • Constance AmesCFO, Principal Financial & Accounting Officer, Treasurer, and Corporate Secretary
  • Andrew FangHead of Business Development

Principais indicadores financeiros

Resultados divulgados pela Tempest Therapeutics, em USD.

Cap. de mercado
8,6 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-3.9
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Tempest Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-26,6 mi-26,3 mi
0-42 mi-41,8 mi
0-29,2 mi-29,5 mi
0-34,6 mi-35,7 mi